Knight Therapeutics (GUD) Insider Trading & Ownership → Gold Mania (From Stansberry Research) (Ad) Free gud Stock Alerts C$5.82 +0.05 (+0.87%) (As of 05:18 PM ET) Add Compare Share Share Insider TradesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider Trades Knight Therapeutics (TSE:GUD) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage46.45%Number OfInsiders Buying(Last 12 Months)1Amount OfInsider Buying(Last 12 Months)C$2.00 MNumber OfInsiders Selling(Last 12 Months)1Amount OfInsider Selling(Last 12 Months)C$750,255.00 Get GUD Insider Trade Alerts Want to know when executives and insiders are buying or selling Knight Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address GUD Insider Buying and Selling by Quarter Ad Stansberry ResearchGold ManiaFormer Goldman VP Reveals Mysterious "Gold Bank" With Huge Upside Potential He says the gains in this should be far greater than just bullion or mining stocks. Some folks had the chance to see 995% the last time we shared this exact "bank". Most people know nothing about it (except the rich and elite).See his free reveal right here. Knight Therapeutics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails4/11/2024Sime ArmoyanInsiderSell10,900C$5.95C$64,855.004/1/2024Sime ArmoyanInsiderBuy6,200C$5.25C$32,550.003/25/2024Sime ArmoyanInsiderBuy351,000C$5.25C$1,842,750.001/22/2024Sime ArmoyanInsiderSell28,200C$5.75C$162,150.001/19/2024Sime ArmoyanInsiderSell91,000C$5.75C$523,250.0010/23/2023Sime ArmoyanInsiderBuy1,100C$4.35C$4,785.009/15/2023Sime ArmoyanInsiderBuy26,400C$4.38C$115,737.60 (Data available from 1/1/2013 forward) GUD Insider Trading Activity - Frequently Asked Questions Who is on Knight Therapeutics's Insider Roster? The list of insiders at Knight Therapeutics includes Arvind Utchanah, Janice Jean Murray, Jonathan Ross Goodman, Long Zone Holdings Inc. , Robert Nathaniel Lande, Samira Sakhia, and Sime Armoyan. Learn more on insiders at GUD. What percentage of Knight Therapeutics stock is owned by insiders? 46.45% of Knight Therapeutics stock is owned by insiders. Learn more on GUD's insider holdings. Which Knight Therapeutics insiders have been buying company stock? The following insiders have purchased GUD shares in the last 24 months: Long Zone Holdings Inc. (C$196,640.00), Samira Sakhia (C$199,998.60), and Sime Armoyan (C$1,995,822.60). How much insider buying is happening at Knight Therapeutics? Insiders have purchased a total of 461,460 GUD shares in the last 24 months for a total of C$2,392,461.20 bought. Which Knight Therapeutics insiders have been selling company stock? The following insider sold GUD shares in the last 24 months: Sime Armoyan (C$1,710,468.05). How much insider selling is happening at Knight Therapeutics? Insiders have sold a total of 295,600 Knight Therapeutics shares in the last 24 months for a total of C$1,710,468.05 sold. More Insider Trading Tools from MarketBeat Related Companies: ACB Insider Trades HLS Insider Trades WEED Insider Trades FRX Insider Trades OPS Insider Trades NBLY Insider Trades WELL Insider Trades HTL Insider Trades SIA Insider Trades MDNA Insider Trades Insider Tracking Tools: CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country: U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles: The 3 Hottest Insiders Buys This Month 3 Companies Buying Back Cheap Stock LatelyPagaya Technologies: An AI Fintech That Insiders Are BuyingThe 5 Stocks Most Sold By Insiders This Year3 Cheap Stocks Insiders are Buying: Investors Should Avoid 1 This page (TSE:GUD) was last updated on 5/2/2024 by MarketBeat.com Staff From Our PartnersUrgent Nvidia WarningAltimetryBiden to Launch “FedNOW” [Move Your Money Now]Priority GoldDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressYour bank is lying to you.MyBankTrackerForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingA.I. is a Tidal Wave - Here’s What to BuyChaikin AnalyticsA once-in-a-century investment opportunityStansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Knight Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.